keyword
MENU ▼
Read by QxMD icon Read
search

Haploidentical transplant

keyword
https://www.readbyqxmd.com/read/29777574/factors-influencing-the-umbilical-cord-blood-stem-cell-industry-an-evolving-treatment-landscape
#1
REVIEW
Carla Dessels, Marco Alessandrini, Michael Sean Pepper
Hematopoietic stem cell transplantation (HSCT) is common practice today for life threatening malignant and non-malignant diseases of the blood and immune systems. Umbilical cord blood (UCB) is rich in hematopoietic stem cells (HSCs) and is an attractive alternative to harvesting HSCs from bone marrow or when mobilized into peripheral blood. One of the most appealing attributes of UCB is that it can be banked for future use and hence provides an off-the-shelf solution for patients in urgent need of a transplantation...
May 18, 2018: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/29773281/-cutaneous-and-systemic-t-cell-lymphoma-treated-with-haploidentical-bone-marrow-transplantation
#2
M Méchineaud, M Mercier, Y Le Corre, A Croué, N Ifrah, L Martin
BACKGROUND: Herein, we report a case of systemic cutaneous T-cell lymphoma refractory to standard therapy, the course of which resulted in haplo-identical bone marrow grafting. PATIENTS AND METHODS: A 53-year-old woman consulted for facial erythema with infiltration, keratotic lesions on the trunk, and adenopathies measuring around 1cm on the axilla and inguinal folds. A diagnosis was made of Sézary syndrome (SS), a leukaemic form of epidermotropic cutaneous T-cell lymphoma...
May 14, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29772350/unmanipulated-haploidentical-hematopoietic-stem-cell-transplantation-achieved-outcomes-comparable-with-matched-unrelated-donor-transplantation-in-young-acquired-severe-aplastic-anemia
#3
Yue Lu, Rui-Juan Sun, Yan-Li Zhao, Min Xiong, Xing-Yu Cao, Jing-Pin Zhang, Zhi-Jie Wei, Jia-Rui Zhou, De-Yan Liu, Dao-Pei Lu
Salvage haploidentical HSCT is considered in patients with severe aplastic anemia (SAA) if matched unrelated donor (MUD) is unavailable. However, studies on haplo- and MUD transplantation in SAA are yet lacking. The present study retrospectively analyzed the outcomes of 89 young SAA patients who underwent unmanipulated alternative hematopoietic stem cell transplantation (HSCT) between September 2012 and September 2016 at our single center. 41 patients received haploidentical donors, and 48 patients received MUD for HSCT...
May 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29770705/gingival-mesenchymal-stem-cells-outperform-haploidentical-dental-pulp-derived-mesenchymal-stem-cells-in-proliferation-rate-migration-ability-and-angiogenic-potential
#4
Ioannis Angelopoulos, Claudia Brizuela, Maroun Khoury
High donor variation makes comparison studies between different dental sources dubious. Dental tissues offer a rare opportunity for comparing the biological characteristics of haploidentical mesenchymal stem cells (MSCs) isolated from the same donor. The objective was to identify the optimal dental source of MSCs through a biological and functional comparison of haploidentical MSCs from gingival (GMSCs) and dental pulp stem cells (DPSCs) focusing mainly on their angiogenic potential. The comparison study included (1) surface markers expression, (2) mesodermal differentiation capacity (chondrogenic, adipogenic, and osteogenic), (3) proliferation, (4) migration potential, (5) ability to form colony units, and (6) angiogenic potential in vitro and in vivo...
January 1, 2018: Cell Transplantation
https://www.readbyqxmd.com/read/29769208/infusion-of-alloanergized-donor-lymphocytes-after-cd34-selected-haploidentical-myeloablative-hematopoietic-stem-cell-transplantation
#5
Jeff K Davies, Lisa L Brennan, John Wingard, Christopher R Cogle, Neena Kapoor, Ami J Shah, Bimalangshu R Dey, Thomas R Spitzer, Marcos De Lima, Laurence Jn Cooper, Peter Thall, Richard E Champlin, Lee M Nadler, Eva C Guinan
PURPOSE: Allogeneic haematopoietic stem-cell transplantation (HSCT) is a curative treatment for many haematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) and delayed immune reconstitution. Alloanergization of donor T-cells is a simple approach to rebuild immunity whilst limiting GvHD after haploidentical HSCT but the optimal T-cell dose and impact on immune reconstitution remain unknown.  Experimental Design: We performed a multicentre Phase 1 trial of alloanergized donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical HSCT...
May 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29764770/haploidentical-stem-cell-transplantation-bone-marrow-vs-peripheral-blood
#6
REVIEW
Zafer Gulbas
Hematopoietic stem cells may be obtained by collection of bone marrow, mobilization and collection of peripheral blood stem cells or umbilical cord blood. Transplantation of peripheral blood hematopoietic cells has increased due to faster engraftment and practicability in both the related, unrelated or haploidentical setting. We reviewed the question of which stem cell source - bone marrow (BM) or peripheral blood (PBSC) - is the most suitable for individuals undergoing haploidentical stem cell transplantation...
April 19, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29758108/comparison-of-transplant-specific-prognostic-scoring-systems-in-haploidentical-transplantation-for-myelodysplastic-syndrome
#7
Seung-Hwan Shin, Young-Woo Jeon, Jae-Ho Yoon, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Yoo-Jin Kim
OBJECTIVES: We intended to identify the predictive abilities of recently published transplant-specific prognostic scoring systems in myelodysplastic syndrome (MDS) patients receiving haploidentical transplantation. METHODS: The outcomes of 73 MDS patients receiving haploidentical transplantation were analyzed, according to the MTPSS, the TRI, and the CIBMTR scoring systems. RESULTS: The median age of patients at transplantation was 50 (range, 19-69) years...
May 14, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29753159/defining-incidence-and-risk-factors-for-catheter-associated-bloodstream-infections-in-an-outpatient-adult-hematopoietic-cell-transplant-program
#8
Marissa K McDonald, Kathryn A Culos, Katie S Gatwood, Caleb Prow, Heidi Chen, Bipin N Savani, Michael Byrne, Adetola A Kassim, Brian G Engelhardt, Madan Jagasia, Gowri Satyanarayana
BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) patients are at an increased risk of developing central line-associated bloodstream infections (CLABSIs) due to prolonged periods of myelosuppression, immunosuppression, and indwelling catheter days. CLABSIs are among the most serious complications in HCT recipients and can lead to prolonged hospitalizations, intensive care unit (ICU) admissions, lengthy antimicrobial therapies, and increased mortality. There is a lack of data regarding the incidence and risk factors associated with the development of CLABSIs in the HCT population undergoing outpatient transplantation...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29751115/evaluation-of-histocheck-as-a-predictor-of-clinical-outcomes-after-haploidentical-hematopoietic-stem-cell-transplantation
#9
Ming-Rui Huo, Dan Li, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is available for nearly all patients without matching human leukocyte antigen (HLA) related or unrelated donors. There was not a valid evaluation system to predict the most proper donor. HistoCheck was based on the functional similarity of amino acids to estimate the allogenicity of HLA mismatches with a sequence similarity matching (SSM) score. We investigated whether HistoCheck could predict clinical outcomes in 500 patients with acute leukemia or myelodysplastic syndrome receiving haplo-HSCT...
May 8, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29750747/haploidentical-donor-transplantation-using-a-novel-clofarabine-containing-conditioning-regimen-for-very-high-risk-hematologic-malignant-neoplasms
#10
Akshay Sharma, Guolian Kang, Anusha Sunkara, Hiroto Inaba, Sima Jeha, Shane J Cross, Terrence Geiger, Brandon Triplett
Recurrent/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell-depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent/refractory or secondary leukemia...
May 10, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29748438/outcomes-of-hematopoietic-stem-cell-transplantation-from-unmanipulated-haploidentical-versus-matched-sibling-donor-in-patients-with-acute-myeloid-leukemia-in-first-complete-remission-with-intermediate-or-high-risk-cytogenetics-a-study-from-the-acute-leukemia
#11
Dalila Salvatore, Myriam Labopin, Annalisa Ruggeri, Giorgia Battipaglia, Ardeshir Ghavamzadeh, Fabio Ciceri, Didier Blaise, William Arcese, Gerard Socié, Jean Henri Bourhis, Mariateresa Van Lint, Benedetto Bruno, Anne Huynh, Stella Santarone, Eric Deconinck, Mohamad Mohty, Arnon Nagler
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option. We compared outcomes of unmanipulated haploidentical to matched sibling donor transplant in acute myeloid leukemia patients in first complete remission. Included were int- and high-risk acute myeloid leukemia in first complete remission undergoing haploidentical and matched sibling donor transplant from 2007-2015 and reported to the ALWP of the EBMT...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29745014/posttransplant-cyclophosphamide-for-haploidentical-stem-cell-transplantation-in-children-with-wiskott-aldrich-syndrome
#12
Yan Yue, Xiaodong Shi, Zeliang Song, Jiayue Qin, Junhui Li, Shunqiao Feng, Rong Liu
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is the curative treatment for Wiskott-Aldrich syndrome (WAS). However, it is difficult to find a matched donor for patients. Therefore, haploidentical donors should be considered for patients lacking a suitable donor. Our pilot study evaluated whether HSCT with posttransplantation cyclophosphamide (PTCy) is an effective treatment for WAS. METHODS: Haploidentical family donors were selected as donor sources for a total of five patients without a suitable donor between March 2015 and March 2017...
May 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29728697/hematopoietic-stem-cell-transplantation-for-adult-sickle-cell-disease-in-the-era-of-universal-donor-availibility
#13
Hafiz Muhammad Aslam, Said Yousuf, Adetola Kassim, Shumaila Muhammad Iqbal, Shahrukh K Hashmi
Current projections estimate that the number of newborns with sickle cell disease (SCD) globally will exceed 400,000 by 2050. Over the last three decades, increased newborn screening, supportive care, and use of hydroxyurea therapy, have decreased early childhood mortality among individuals affected with SCD. Despite hematopoietic cell transplantation (HCT) being curative in SCD, its impact on disease free survival remains unknown, especially in adults, partly due to previous limitations in donor options and perceived mortality in adults using myeloablative conditioning...
May 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29716416/allogeneic-transplantation-for-relapsed-and-refractory-hodgkin-lymphoma-long-term-outcomes-and-graft-versus-host-disease-free-relapse-free-survival
#14
Francesco Spina, Tommaso Radice, Chiara De Philippis, Martina Soldarini, Maria Chiara Di Chio, Anna Dodero, Anna Guidetti, Simonetta Viviani, Paolo Corradini
This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18-60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%)...
May 1, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29706356/haploidentical-stem-cell-transplantation-t-cell-depleted-and-repleted
#15
REVIEW
Z Gokgoz, O Arslan
Allogeneic hematopoietic stem cell transplantation (AHSCT), is a curative treatment option for many hematological diseases. Donor availability is the major limiting factor in the transplantation setting. More than half of the patients do not have a HLA fully matched related/unrelated donor but almost all patients have an haploidentical donor. Haploidentical transplantion can be performed either as T cell depleted or repleted. Despite the promising results in T cell depletion methods, expensive T cell selection and the necessity for experienced staff seem to be the limiting factors...
April 19, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29703966/cd3-graft-cell-count-influence-on-chronic-gvhd-in-haploidentical-allogeneic-transplantation-using-post-transplant-cyclophosphamide
#16
A Mussetti, C De Philippis, C Carniti, M Bastos-Oreiro, J Gayoso, N Cieri, M Pennisi, F Ciceri, R Greco, J Peccatori, F Patriarca, J Mariotti, L Castagna, P Corradini
The effects of graft or donor characteristics in haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PT-Cy) are largely unknown. In this multicenter retrospective study we analyzed the correlations between graft cell composition (CD34+, CD3+) and donor features on transplant outcomes in 234 patients who underwent HCT between 2010 and 2016. On multivariate analysis, the use of peripheral blood stem cells (PBSC) was associated with an increased incidence of grade 2-4 acute GVHD [HR 1...
April 27, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29700172/the-early-expansion-of-anergic-nkg2apos-cd56dim-cd16neg-natural-killer-cells-represents-a-therapeutic-target-in-haploidentical-haematopoietic-stem-cell-transplantation
#17
Alessandra Roberto, Clara Di Vito, Elisa Zaghi, Emilia Maria Cristina Mazza, Arianna Capucetti, Michela Calvi, Paolo Tentorio, Veronica Zanon, Barbara Sarina, Jacopo Mariotti, Stefania Bramanti, Elena Tenedini, Enrico Tagliafico, Silvio Bicciato, Armando Santoro, Mario Roederer, Emanuela Marcenaro, Luca Castagna, Enrico Lugli, Domenico Mavilio
Natural Killer cells are the first lymphocyte population to reconstitute early after non myelo-ablative and T cell-replete haploidentical hematopoietic stem cell transplantation with post-transplant infusion of cyclophosphamide. The present study characterizes the transient and predominant expansion starting from the 2nd week after haploidentical hematopoietic stem cell transplantation of a donor-derived unconventional subset of NKp46neg-low/CD56dim/CD16neg natural killer cells expressing remarkable high levels of CD94/NKG2A...
April 26, 2018: Haematologica
https://www.readbyqxmd.com/read/29685953/outcomes-of-medicare-age-eligible-nhl-patients-receiving-ric-allogeneic-transplantation-a-cibmtr-analysis
#18
Nirav N Shah, Kwang Woo Ahn, Carlos Litovich, Timothy S Fenske, Sairah Ahmed, Minoo Battiwalla, Nelli Bejanyan, Parastoo B Dahi, Javier Bolaños-Meade, Andy I Chen, Stefan O Ciurea, Veronika Bachanova, Zachariah DeFilipp, Narendranath Epperla, Nosha Farhadfar, Alex F Herrera, Bradley M Haverkos, Leona Holmberg, Nasheed M Hossain, Mohamed A Kharfan-Dabaja, Vaishalee P Kenkre, Hillard M Lazarus, Hemant S Murthy, Taiga Nishihori, Andrew R Rezvani, Anita D'Souza, Bipin N Savani, Matthew L Ulrickson, Edmund K Waller, Anna Sureda, Sonali M Smith, Mehdi Hamadani
The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged ≥65 years (older cohort; n = 446) compared with a cohort of younger NHL patients aged 55-64 years (n = 1183). We identified 1629 NHL patients undergoing a first reduced-intensity conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the United States...
April 24, 2018: Blood Advances
https://www.readbyqxmd.com/read/29680516/peripheral-blood-grafts-for-t-cell-replete-haploidentical-transplantation-increase-the-incidence-and-severity-of-cytokine-release-syndrome
#19
Renju V Raj, Mehdi Hamadani, Aniko Szabo, Marcelo C Pasquini, Nirav N Shah, William R Drobyski, Bronwen E Shaw, Wael Saber, J Douglas Rizzo, James Jerkins, Timothy S Fenske, Anita D'Souza, Binod Dhakal, Chao Zhang, Steve Konings, Parameswaran N Hari, Saurabh Chhabra
T-cell replete post-transplant cyclophosphamide (PT-CY)-based protocols have led to increasing use of haploidentical allogeneic hematopoietic cell transplantation (haploHCT). With this approach, bidirectional alloreactivity causing non-engraftment or severe graft-versus-host disease (GVHD) are no longer major barriers to haploHCT. PT-CY eliminates alloreactive lymphocytes but spares CD34+ stem cells and regulatory T lymphocytes, resulting in reliable hematopoietic recovery with relatively low incidence of GVHD...
April 19, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29677078/therapeutic-outcomes-of-haploidentical-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-severe-aplastic-anemia-a-multicenter-study
#20
Yonghua Li, Fengqi Duan, Haowen Xiao, Xiaoxiong Wu, Shunqing Wang, Duorong Xu, Qifa Liu, Zhiping Fan, Danian Nie, Yongrong Lai, Bingyi Wu, Dongjun Lin, Xin Du, Jianyu Weng, Xin Du, Zujun Jiang, Yan Pang, Lin Ouyang, Zenghui Liu, Leqin Zhang, Na Han, Lixuan Chen, Yang Xiao
BACKGROUND: Haploidentical donor allogeneic hematopoietic stem cell transplantation (HID-HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA. METHODS: A total of 235 SAA patients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included...
April 19, 2018: Transplantation
keyword
keyword
13298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"